

Historical Information

Provided by: Senhwa Biosciences, Inc.

SEQ_NO	1	Date of announcement	2025/03/31	Time of announcement	18:32:13
Subject	Due to strategic considerations, the Company decides to terminate patient enrollment early for the phase II clinical trial of Community-Acquired Pneumonia.				
Date of events	2025/03/31	To which item it meets	paragraph 53		

Statement	<p>1.Date of occurrence of the event:2025/03/31 2.Company name:Senhwa Biosciences Inc. 3.Relationship to the Company (please enter "head office" or "subsidiaries"):Headquarter 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence: (1)Due to strategic considerations, as well as contributing factors such as achieving approximately half of the targeted enrollment, observing preliminary clinical signals, and the passing of the peak season for influenza and COVID-19 infections, which may adversely affect patient enrollment, the Company has decided to issue formal notifications to seven trial centers, including National Taiwan University Hospital, of its resolution to terminate patient enrollment ahead of schedule for the Phase II clinical trial of Silmitasertib (CX-4945) in the treatment of community-acquired pneumonia (CAP) associated with SARS-CoV-2 and influenza viral infections. The study will proceed to unblinding upon completion of the patient follow-up period specified in the trial protocol. (2)For details regarding the Phase II clinical trial of Silmitasertib (CX-4945) for the treatment of community-acquired pneumonia (CAP), please refer to the Company's major announcement on December 25, 2023. (3)A single clinical trial result does not reflect the success or failure of new drug development and launch in the future. Investors should make prudent judgments and investments. 6.Countermeasures:The Company will implement early termination of patient enrollment for the aforementioned phase II clinical trial of Community-Acquired Pneumonia (CAP), prioritizing resources toward clinical development projects with greater potential. The Company will upload the important information on Market Observation Post System. 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None. Drug development requires huge amount of time and investment, and there is no guarantee of success, which may put the investment at risk. Investors should make prudent judgments on investments.</p>
-----------	---